Tafamidis

Jul 11, 2023

Amyloidosis now a hot topic in cardiac imaging due to new drug treatment

Jan 29, 2023

Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: a plain language summary

Dec 19, 2021

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy

May 17, 2018

Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis

U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease

ESC: Tafamidis Cuts Deaths, Admissions in TTR Cardiac Amyloidosis

Treatment with the investigational drug tafamidis was associated with a reduction in all-cause mortality and cardiovascular hospitalizations in patients with…

US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy

Subscribe to

RNAi Explained

Dr. Bersell explores RNA interference (RNAi) technology and its applications in treating ATTR-CM and ATTR-PN. Learn about mechanism of action, clinical evidence, and patient outcomes.

Learn More

Expert Perspectives on Attruby®

Dr. Barry Trachtenberg and ATTR community members discuss Attruby™ (acoramidis), covering clinical data, patient perspectives, and treatment considerations.

Watch Discussion